175 related articles for article (PubMed ID: 26631547)
1. Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study.
Ding K; Wu S; Ying W; Pan Q; Li X; Zhao D; Li X; Zhao Q; Zhu Y; Ren H; Qian X
Sci Rep; 2015 Dec; 5():17564. PubMed ID: 26631547
[TBL] [Abstract][Full Text] [Related]
2. Validation of a multi-omics strategy for prioritizing personalized candidate driver genes.
Liang L; Song L; Yang Y; Tian L; Li X; Wu S; Huang W; Ren H; Tang N; Ding K
Oncotarget; 2016 Jun; 7(25):38440-38450. PubMed ID: 27469031
[TBL] [Abstract][Full Text] [Related]
3. Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model.
Yang Z; Jia M; Liu G; Hao H; Chen L; Li G; Liu S; Li Y; Wu CI; Lu X; Wang S
PLoS One; 2017; 12(11):e0187551. PubMed ID: 29117265
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Löffler MW; Mohr C; Bichmann L; Freudenmann LK; Walzer M; Schroeder CM; Trautwein N; Hilke FJ; Zinser RS; Mühlenbruch L; Kowalewski DJ; Schuster H; Sturm M; Matthes J; Riess O; Czemmel S; Nahnsen S; Königsrainer I; Thiel K; Nadalin S; Beckert S; Bösmüller H; Fend F; Velic A; Maček B; Haen SP; Buonaguro L; Kohlbacher O; Stevanović S; Königsrainer A; ; Rammensee HG
Genome Med; 2019 Apr; 11(1):28. PubMed ID: 31039795
[TBL] [Abstract][Full Text] [Related]
5. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma.
Woo HG; Kim SS; Cho H; Kwon SM; Cho HJ; Ahn SJ; Park ES; Lee JS; Cho SW; Cheong JY
PLoS One; 2014; 9(12):e115152. PubMed ID: 25521761
[TBL] [Abstract][Full Text] [Related]
6. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma.
Ikeda A; Shimizu T; Matsumoto Y; Fujii Y; Eso Y; Inuzuka T; Mizuguchi A; Shimizu K; Hatano E; Uemoto S; Chiba T; Marusawa H
Gastroenterology; 2014 Jan; 146(1):222-32.e35. PubMed ID: 24055508
[TBL] [Abstract][Full Text] [Related]
7. DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma.
Zhang G; Tang X; Liang L; Zhang W; Li D; Li X; Zhao D; Zheng Y; Chen Y; Hao B; Wang K; Tang N; Ding K
Oncogene; 2020 Apr; 39(16):3229-3244. PubMed ID: 32071398
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers.
Shiraishi Y; Fujimoto A; Furuta M; Tanaka H; Chiba K; Boroevich KA; Abe T; Kawakami Y; Ueno M; Gotoh K; Ariizumi S; Shibuya T; Nakano K; Sasaki A; Maejima K; Kitada R; Hayami S; Shigekawa Y; Marubashi S; Yamada T; Kubo M; Ishikawa O; Aikata H; Arihiro K; Ohdan H; Yamamoto M; Yamaue H; Chayama K; Tsunoda T; Miyano S; Nakagawa H
PLoS One; 2014; 9(12):e114263. PubMed ID: 25526364
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma.
Imbeaud S; Ladeiro Y; Zucman-Rossi J
Semin Liver Dis; 2010 Feb; 30(1):75-86. PubMed ID: 20175035
[TBL] [Abstract][Full Text] [Related]
10. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Yeh SH; Wu DC; Tsai CY; Kuo TJ; Yu WC; Chang YS; Chen CL; Chang CF; Chen DS; Chen PJ
Clin Cancer Res; 2006 Feb; 12(4):1097-108. PubMed ID: 16489062
[TBL] [Abstract][Full Text] [Related]
11. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide detection of allelic gene expression in hepatocellular carcinoma cells using a human exome SNP chip.
Park YM; Cheong HS; Lee JK
Gene; 2014 Nov; 551(2):236-42. PubMed ID: 25192659
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.
Furukawa T; Sakamoto H; Takeuchi S; Ameri M; Kuboki Y; Yamamoto T; Hatori T; Yamamoto M; Sugiyama M; Ohike N; Yamaguchi H; Shimizu M; Shibata N; Shimizu K; Shiratori K
Sci Rep; 2015 Mar; 5():8829. PubMed ID: 25743105
[TBL] [Abstract][Full Text] [Related]
14. The mutational landscape of hepatocellular carcinoma.
Lee JS
Clin Mol Hepatol; 2015 Sep; 21(3):220-9. PubMed ID: 26523267
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations.
Bjersing L; Andersson C; Lithner F
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):393-7. PubMed ID: 9162306
[TBL] [Abstract][Full Text] [Related]
16. Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis.
Chen Y; Wang L; Xu H; Liu X; Zhao Y
Oncol Rep; 2013 Oct; 30(4):1906-12. PubMed ID: 23912677
[TBL] [Abstract][Full Text] [Related]
17. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
18. A Significant Regulatory Mutation Burden at a High-Affinity Position of the CTCF Motif in Gastrointestinal Cancers.
Umer HM; Cavalli M; Dabrowski MJ; Diamanti K; Kruczyk M; Pan G; Komorowski J; Wadelius C
Hum Mutat; 2016 Sep; 37(9):904-13. PubMed ID: 27174533
[TBL] [Abstract][Full Text] [Related]
19. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.
Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q
Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766
[TBL] [Abstract][Full Text] [Related]
20. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
